The announcement of a class action lawsuit against Kyverna Therapeutics for alleged securities violations related to their IPO is likely to create negative sentiment among investors. Legal issues can lead to uncertainty and potential financial liabilities, which often result in a decline in stock prices. Given the direct mention of the lawsuit and its potential implications, the relevance and importance are high.